ABVX ABIVAX Société Anonyme

NASDAQ
$91.06

ABIVAX Société Anonyme (ABVX) is expected to report earnings on December 21, 2026, after the market close. The consensus earnings estimate is a loss of $1.27 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.4% since its last earnings release on September 21, 2026.

ABIVAX Société Anonyme Missed Consensus Estimates
Monday, September 21, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Dec 21
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($1.27)
Rev est $1.6M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $95.00

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ABIVAX Société Anonyme

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.